Cardiac arrhythmia-detection startup BioSig Technologies (NSDQ:BSGM) has raised $3.26 million for a subsidiary that is developing more applications for its electrogram-evaluation technology.
The company attributed the funding round to 17 investors, according to a regulatory filing. It began the offering on August 5 with a goal of raising $3.6 million.
BioSig formed NeuroClear Technologies in November of 2018 to pursue additional applications of its PURE (Precise Uninterrupted Real-time evaluation of Electrograms) EP signal processing technology outside of the field of electrophysiology. BioSig CEO Kenneth Londoner holds the same title for NeuroClear.
BioSig EVP Natasha Drapeau confirmed in an email to MassDevice that the funding is for NeuroClear, but declined to elaborate.
In July, BioSig received $1 million in funding from the Mayo Clinic after working with the healthcare organization for two years.
BioSig recently completed first-in-human studies at the Rochester, Minn.-based clinic aimed at validating the safety and efficacy of its Pure EP system during mapping and ablation procedures in a cardiac EP lab. Patient studies were also conducted at Texas Cardiac Arrhythmia Institute at St. David’s Medical Center and at Greenville Memorial in North Carolina, according to the Westport, Conn.-based company. Previously, BioSig conducted preclinical studies at Mayo.